Novo Nordisk hopes to stabilize Wegovy supply in early 2022

Production of obesity drug Wegovy is still expected to experience delays for the rest of 2021, but should, however, be stabilized in early 2022, the pharmaceutical company reports.

Photo: Novo Nordisk / PR

Novo Nordisk has significantly increased the production of its weight loss drug Wegovy, which is in high demand, and is now hoping to have stabilized its supply early next year, the company writes in an update on its website.

Depending on the demand for the drug, production may still be affected by delays for the rest of 2021, before stabilizing in 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs